FDA approves two sickle cell anemia treatments, one using CRISPR gene editing – The New York Times
On Friday, the Food and Drug Administration approved the first gene-editing therapy ever used in humans to treat sickle cell anemia, a debilitating blood disorder caused by a single mutated gene. The agency also approved a second conventional gene therapy treatment for sickle cell disease that does not use gene editing. For the 100,000 sick … [Read more…]